Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964281 | 0.83 | TP53 (0.44) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL4486230 | 0.82 | ALDH1A1 (0.47) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL13254838 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL11980468 | 0.80 | ALDH1A1 (0.46) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL13598984 | 0.78 | ALDH1A1 (0.53) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL9917296 | 0.78 | ALDH1A1 (0.45) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL3749547 | 0.78 | ALDH1A1 (0.42) | ALDH1A1ATMNPSR1TSHRFABP6 | |
| SCHEMBL4402796 | 0.78 | ALDH1A1 (0.44) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL23387623 | 0.77 | ALDH1A1 (0.47) | ALDH1A1ATMTP53L3MBTL1NPSR1 | |
| SCHEMBL22123216 | 0.77 | ALDH1A1 (0.44) | ALDH1A1ATMTP53L3MBTL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | ALDH1A1 515/4885ATM 1816/4885TP53 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.